This is part of its efforts to popularize science to the general public and students who are pursuing science as their career. TNSF attempt to focus on students on higher science as everyone knows that learning of science at college within the curriculum is not enough to acquire holistic knowledge of science at the appropriate time. Hence, to fill the gap between what students are acquiring through the curriculum and what it is required, TNSF is planning its activities on higher science to students who are pursuing higher education.
About the Lecture
For the first time, a new gene editing technology called base editing was used to modify immune cells and successfully treat a teen with treatment-resistant leukemia. A month afterward, 13-year-old Alyssa was in remission, and she continues to do well several months later.
The treatment is a modification of chimeric antigen receptor, or CAR, T-cell therapy. But instead of using the CRISPR gene editing technique to modify the patient’s immune cells, the clinicians used the more precise base editing technique to alter donor immune cells.
Introduction
Dr. Priya Ramanathan
Assistant Professor, The Cancer Institute (WIA), Adyar, Chennai
Lymphoblastic Leukemia
Dr. Indumathi Mariappan
Research Scientist, Hyderabad Research Foundation, LVPEI,
Member, Task Force on Stem Cell Research & Regenerative Medicine
Possibilities of correcting Genetic Defects
Dr. V. Aravindhan
Associate Professor, Department of Genetics, University of Madras
Brainstorming Session on Gene Therapy
Conclusion
Dr. Priya Ramanathan, is Associate Professor, Cancer Institute(WIA) Adyar, Chennai. Dr. Priya Ramanathan has been working in the field of cancer Immunotherapy for the past 15 years. She had the opportunity to develop the first dendritic cell vaccine therapy program in the country for cervical cancer patients and test the same in a phase I trial. The same has now been extended to phase II. She is currently working on the same along with a dendritic cell vaccine programme using a recombinant SPAG9 protein which was discovered as tumor associated protein. Have published a no. of papers relating to cancer immunotherapy in general and dendritic cell vaccines in particular as well as immune suppression in cancer. Exploring immunotherapeutic options for other cancers is of special interest as well.
Dr. Indumathi Mariappan, completed her doctoral training in the area of Cell Biology and Molecular Biology at the Centre for Cellular and Molecular Biology (CCMB), Hyderabad in the year 2005. She also underwent a three year post-doctoral training at CCMB before joining the Stem Cell Biology Laboratory at LVPEI in 2008. Dr Mariappan's lab is involved in basic and translational research towards addressing the problems of retinal and corneal diseases using different sources of adult and pluripotent stem cells. Her group is currently exploring the basic biology of limbal stem cells and the applications of embryonic stem cells (hESCs) and patient-specific induced pluripotent stem cells (hiPSCs) in disease modeling and regenerative medicine.
Dr. V. Aravindhan, an Assitant Professor in the Department of Genetics at Madras University did his Ph.D. in Molecular Biology and Vaccine Research. He moved to the USA for his Post-doctoral research work and joined with Food and Drug Administration. He later moved to National Cancer Institute at Fredrick in the USA. He moved back to India and take up the Scientist position in Dept of Transcriptomics and Molecular Immunology, at Madras Diabetes Research Foundation. He later joined Anna University as a Scientist, Laboratory of Molecular Immunology, Life Sciences, AU-KBC, Anna University, MIT campus before taking up a teaching position at Madras University. He has published more than 35 papers.